Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Pipeline Review, H2 2017

  • ID: 4432183
  • Report
  • 22 pages
  • Global Markets Direct
1 of 5
Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Pipeline Review, H2 2017

Summary

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Heat shock protein 75 kDa mitochondrial is a protein that is encoded by the TRAP1 gene. It is a negative regulator of mitochondrial respiration able to modulate the balance between oxidative phosphorylation and aerobic glycolysis. This protein may function in regulating cellular stress responses.

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Glioblastoma Multiforme (GBM), Metastatic Brain Tumor and Neurofibromatoses Type II.

The latest report Heat Shock Protein 75 kDa Mitochondrial - Pipeline Review, H2 2017, outlays comprehensive information on the Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1)
  • The report reviews Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Overview

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Companies Involved in Therapeutics Development

Plex Pharmaceuticals Inc

Heat Shock Protein 75 kDa Mitochondrial (TNFR Associated Protein 1 or Tumor Necrosis Factor Type 1 Receptor Associated Protein or HSP 75 or TRAP1) - Drug Profiles

Panvotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hsp90 and TRAP1 for Glioblastoma Multiforme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hsp90 and TRAP1 for Metastatic Brain Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SMTIN-P01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Plex Pharmaceuticals Inc, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Plex Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll